OliX Pharmaceuticals (KOSDAQ:A226950) - Stock Price, News & Analysis

A226950 Stock Overview

Focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases.

A226950 fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Rewards

Risk Analysis

Has less than 1 year of cash runway

Earnings have declined by 10.8% per year over past 5 years

Highly volatile share price over the past 3 months

Shareholders have been diluted in the past year

OliX Pharmaceuticals, Inc Competitors

Qurient

KOSDAQ:A115180

₩143.5b

TiumBio

KOSDAQ:A321550

₩166.3b

ISU Abxis

KOSDAQ:A086890

₩246.3b

CG Invites

KOSDAQ:A083790

₩190.2b

Price History & Performance

Summary of all time highs, changes and price drops for OliX Pharmaceuticals
Historical stock prices
Current Share Price	₩11,820.00
52 Week High	₩25,950.00
52 Week Low	₩8,280.00
Beta	0.79
11 Month Change	-26.58%
3 Month Change	-18.09%
1 Year Change	-26.36%
33 Year Change	-73.38%
5 Year Change	-35.59%
Change since IPO	-63.96%

We Think OliX Pharmaceuticals (KOSDAQ:226950) Has A Fair Chunk Of Debt

Jul 22

It's Down 36% But OliX Pharmaceuticals, Inc (KOSDAQ:226950) Could Be Riskier Than It Looks

Jun 25

Recent updates

We Think OliX Pharmaceuticals (KOSDAQ:226950) Has A Fair Chunk Of Debt

Jul 22

It's Down 36% But OliX Pharmaceuticals, Inc (KOSDAQ:226950) Could Be Riskier Than It Looks

Jun 25

OliX PharmaceuticalsInc (KOSDAQ:226950) Is Using Debt Safely

Apr 13

Introducing OliX PharmaceuticalsInc (KOSDAQ:226950), The Stock That Zoomed 150% In The Last Year

Feb 17

Shareholder Returns

	A226950	KR Biotechs	KR Market
7D	-6.0%	1.5%	1.9%
1Y	-26.4%	38.5%	5.0%

Return vs Industry: A226950 underperformed the KR Biotechs industry which returned 38.5% over the past year.

Return vs Market: A226950 underperformed the KR Market which returned 5% over the past year.

Price Volatility

Is A226950's price volatile compared to industry and market?
A226950 volatility
A226950 Average Weekly Movement	12.5%
Biotechs Industry Average Movement	9.5%
Market Average Movement	6.5%
10% most volatile stocks in KR Market	12.1%
10% least volatile stocks in KR Market	3.4%

Stable Share Price: A226950's share price has been volatile over the past 3 months.

Volatility Over Time: A226950's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of KR stocks.

About the Company

Founded	Employees	CEO	Website
2010	72	Dong-Ki Lee	www.olixpharma.com

OliX Pharmaceuticals, Inc. focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases. The company’s products pipeline includes OLX101A for skin scar; OLX201A for idiopathic pulmonary fibrosis; OLX301 for age-related macular degeneration; and OLX301D for subretinal fibrosis. The company has a collaboration agreement with Théa to develop SiRNA therapeutics for ophthalmic diseases; and a research collaboration with PCI Biotech Holding ASA.

OliX Pharmaceuticals, Inc Fundamentals Summary

How do OliX Pharmaceuticals's earnings and revenue compare to its market cap?
A226950 fundamental statistics
Market cap	₩200.63b
Earnings (TTM)	-₩19.72b
Revenue (TTM)	₩17.90b

11.2x

P/S Ratio

-10.2x

P/E Ratio

Is A226950 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A226950 income statement (TTM)
Revenue	₩17.90b
Cost of Revenue	₩222.79m
Gross Profit	₩17.68b
Other Expenses	₩37.40b
Earnings	-₩19.72b

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-1.16k
Gross Margin	98.76%
Net Profit Margin	-110.18%
Debt/Equity Ratio	166.8%

How did A226950 perform over the long term?

See historical performance and comparison

A226950 Stock Overview

Rewards

Risk Analysis

OliX Pharmaceuticals, Inc Competitors

KOSDAQ:A115180

₩143.5b

KOSDAQ:A321550

₩166.3b

KOSDAQ:A086890

₩246.3b

KOSDAQ:A083790

₩190.2b

Price History & Performance

Recent News & Updates

Second quarter 2024 earnings released: ₩578 loss per share (vs ₩646 loss in 2Q 2023)

We Think OliX Pharmaceuticals (KOSDAQ:226950) Has A Fair Chunk Of Debt

It's Down 36% But OliX Pharmaceuticals, Inc (KOSDAQ:226950) Could Be Riskier Than It Looks

New minor risk - Share price stability

OliX Pharmaceuticals, Inc announced that it has received KRW 14.7 billion in funding from a group of investors

Full year 2023 earnings released: ₩1,324 loss per share (vs ₩1,877 loss in FY 2022)

Recent updates

Second quarter 2024 earnings released: ₩578 loss per share (vs ₩646 loss in 2Q 2023)

We Think OliX Pharmaceuticals (KOSDAQ:226950) Has A Fair Chunk Of Debt

It's Down 36% But OliX Pharmaceuticals, Inc (KOSDAQ:226950) Could Be Riskier Than It Looks

New minor risk - Share price stability

OliX Pharmaceuticals, Inc announced that it has received KRW 14.7 billion in funding from a group of investors

Full year 2023 earnings released: ₩1,324 loss per share (vs ₩1,877 loss in FY 2022)

OliX Pharmaceuticals, Inc Receives HREC Approval to Initiate Phase 1 Clinical Trial of NASH and Obesity Drug

OliX Pharmaceuticals Announces Positive Safety Data and Preliminary Efficacy Effects in a Phase 1 Trial of OLX10212 for Age-Related Macular Degeneration

Third quarter 2023 earnings released: ₩346 loss per share (vs ₩385 loss in 3Q 2022)

New minor risk - Shareholder dilution

OliX Pharmaceuticals, Inc. Announces First Patient in Phase 1 Clinical Study of RNAi Therapeutic OLX72021 for Androgenic Alopecia

OliX Pharmaceuticals, Inc. Presents Preclinical Data Showing Synergistic Weight Loss from Anti-NASH siRNA and Semaglutide Combination Treatment

Full year 2022 earnings released: ₩1,877 loss per share (vs ₩2,088 loss in FY 2021)

Olix Pharmaceuticals Publishes Preclinical Research Demonstrating Olx104c’S Potential as an Effective Treatment for Hair Loss

No independent directors

OliX Pharmaceuticals, Inc Receives IND Approval from FDA to Develop RNAi Therapeutic OLX10212 for Age-Related Macular Degeneration

OliX Pharmaceuticals, Inc. Announces IND Submission to U.S. FDA to Evaluate Safety and Tolerability of OLX10212 in Phase 1 Clinical Trial

Olix Pharmaceuticals Announces Completion of Enrollment in Phase 2 Clinical Trial of Olx101a in Patients with Hypertrophic Scars

OliX Pharmaceuticals, Inc announced that it has received KRW 57 billion in funding from a group of investors

OliX Pharmaceuticals, Inc announced that it expects to receive KRW 15.000139 billion in funding from Shinhan Capital Co., Ltd. and other investors

Olix Pharmaceuticals,Inc Identifies Effective Inhibition of Target Gene Expression and Delivery of Candidate to Brain for CNS Therapeutics

No independent directors

OliX Pharmaceuticals,Inc Identifies Inhibition of Target Gene Expression in Nonhuman Primate Models for NASH Candidate

OliX Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for Improved Intracellular Delivery Platform Technology for RNAi Therapeutics

OliX PharmaceuticalsInc (KOSDAQ:226950) Is Using Debt Safely

Full year 2020 earnings released: ₩1,474 loss per share (vs ₩1,102 loss in FY 2019)

New 90-day low: ₩38,800

Introducing OliX PharmaceuticalsInc (KOSDAQ:226950), The Stock That Zoomed 150% In The Last Year

OliX Pharmaceuticals, Inc. Announces Results from Preclinical Study of Hair Loss Therapeutic Candidate

New 90-day high: ₩58,500

Third quarter 2020 earnings released: ₩639 loss per share

New 90-day high: ₩77,000

OliX Pharmaceuticals Announces FDA Clearance of the IND to Evaluate the Efficacy of OLX10010 in Phase 2a Clinical Trial for Hypertrophic Scars

OliX Pharmaceuticals, Inc. Announces Expansion of Collaboration with Laboratoires Théa to Develop SiRNA Therapeutics for Ophthalmic Diseases

New 90-day high: ₩64,100

OliX Pharmaceuticals, Inc. Announces IND Submission to U.S. FDA to Evaluate the Efficacy of OLX10010 in Phase 2a Clinical Trial

New 90-day high - ₩58,600

First half earnings released

New 90-day high - ₩53,700

Shareholder Returns

Price Volatility

About the Company

OliX Pharmaceuticals, Inc Fundamentals Summary

11.2x

-10.2x

Earnings & Revenue